MedTrace Logo

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

NCT06765668 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-08-24

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

Conditions

  • Parkinson Disease

Interventions

DRUG

CREXONT ER

CREXONT ER capsule.

Sponsors & Collaborators

  • Amneal Pharmaceuticals, LLC

    collaborator INDUSTRY

  • Impax Laboratories, LLC

    lead INDUSTRY

Principal Investigators

  • Hester Visser, MD · Amneal Pharmaceuticals, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-12
Primary Completion
2025-11-30
Completion
2026-08-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765668 on ClinicalTrials.gov